Scancell Holdings plc (AIM:SCLP)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 113.04M +11.7% |
| Revenue (ttm) | n/a |
| Net Income | -17.90M |
| EPS | -0.02 |
| Shares Out | 1.21B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 488,493 |
| Open | 9.34 |
| Previous Close | 9.35 |
| Day's Range | 9.30 - 9.40 |
| 52-Week Range | 9.10 - 29.50 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 25.50 (+173.46%) |
| Est. Earnings | Oct 28, 2026 |
About Scancell Holdings
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SCLP stock is "Strong Buy." The 12-month stock price target is 26p, which is an increase of 173.46% from the latest price.
News
Scancell FY26 Loss Widens; ISCIB1+ Phase 2 SCOPE Data Due In 2027
(RTTNews) - On Friday, Scancell Holdings plc (SCLP), a clinical-stage biopharmaceutical company, reported preliminary unaudited financial results for the year ended April 30, 2026.
Scancell Holdings Annual report: H2 2026
Scancell Holdings has published its H2 2026 annual report on October 9, 2026.
Scancell Secures Up To $25 Mln Debt Facility To Fund ISCIB1+ Phase 3
(RTTNews) - Scancell Holdings plc (SCLP.L) on Thursday announced it has entered into a loan agreement with funds and accounts managed by BlackRock for a debt facility of up to $25 million.
Scancell Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The session highlighted strong phase II results for iSCIB1+ in advanced melanoma, a robust regulatory and financial position post-merger, and a clear path to phase III and commercial expansion. Multiple pipeline assets and near-term catalysts support growth and collaboration.
Scancell Holdings Slides: Corporate presentation
Scancell Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additi...
Scancell Holdings Earnings Call Transcript: H1 2026
Lead asset iSCIB1+ achieved 74% PFS at 16 months in melanoma, with FDA phase III clearance and strong patent protection. Cash runway extends into H2 2026, with multiple financing and partnering options under evaluation. Blockbuster market potential and diversified pipeline support long-term growth.
Scancell Holdings Quarterly report: H1 2026
Scancell Holdings has published its H1 2026 quarterly earnings report on January 29, 2026.
Scancell Holdings Slides: H1 2026
Scancell Holdings has posted slides in relation to its H1 2026 quarterly earnings report, which was published on January 29, 2026.
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-poin...
Scancell Holdings Transcript: Study update
Phase II SCOPE study of iSCIB1+ in advanced melanoma showed a 74% PFS at 16 months and strong disease control, with favorable safety and robust T cell responses. Regulatory agencies support phase III plans, and commercialization is targeted for late 2029.
Scancell Holdings Press release: Study update
Scancell Holdings issued a press release on December 11, 2025, disclosing material business information to investors.
Scancell Holdings Slides: Study update
Scancell Holdings has posted slides in relation to its latest quarterly earnings report, which was published on December 11, 2025.
Scancell Holdings Earnings Call Transcript: H2 2025
Strong clinical results for iSCIB1+ in advanced melanoma and robust financial position support late-stage development, with regulatory and partnership discussions underway. Cash runway extends into 2026, and milestone payments from Genmab are anticipated within 12 months.
Scancell Holdings Annual report: H2 2025
Scancell Holdings has published its H2 2025 annual report on September 11, 2025.
Scancell Holdings Annual report: H2 2025
Scancell Holdings has published its H2 2025 annual report on September 11, 2025.
Scancell Holdings Slides: H2 2025
Scancell Holdings has posted slides in relation to its H2 2025 quarterly earnings report, which was published on September 11, 2025.
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a b...
Scancell Holdings Transcript: Study update
Phase II data for iSCIB1+ in advanced melanoma showed a 68.6% response rate and 69% PFS at 22 months, outperforming standard of care by 20%. Safety was excellent, and a biomarker enables precise patient selection for phase III. Strong commercial and regulatory prospects highlighted.
Scancell Holdings Press release: Study update
Scancell Holdings issued a press release on July 22, 2025, disclosing material business information to investors.
Scancell Holdings Slides: Study update
Scancell Holdings has posted slides in relation to its latest quarterly earnings report, which was published on July 22, 2025.
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety
Scancell Holdings Transcript: Status update
Significant progress continues in clinical and corporate strategy, with SCOPE study data on track for July and year-end, and the launch of GlyMab Therapeutics to unlock antibody portfolio value. Financial position is strong, with ongoing partnerships and regulatory planning supporting future growth.
Scancell Holdings Press release: Status update
Scancell Holdings issued a press release on June 25, 2025, disclosing material business information to investors.
Scancell Holdings Transcript: Investor update
Lead immunotherapy and antibody assets are advancing with strong clinical data, strategic partnerships, and a robust financial position. Multiple value inflection points are expected in 2025, with regulatory and partnering strategies in place to maximize shareholder value.